These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10191234)

  • 61. Appearance of autologous neutralizing antibody correlates with reduction in virus load and phenotype switch during primary infection with human immunodeficiency virus type 1.
    Lathey JL; Pratt RD; Spector SA
    J Infect Dis; 1997 Jan; 175(1):231-2. PubMed ID: 8985228
    [No Abstract]   [Full Text] [Related]  

  • 62. Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity.
    Euler Z; van den Kerkhof TL; van Gils MJ; Burger JA; Edo-Matas D; Phung P; Wrin T; Schuitemaker H
    J Virol; 2012 Feb; 86(4):2045-55. PubMed ID: 22156522
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Recent and long-lasting infections: the need for avidity testing in HIV-1 infected subjects.
    Re MC; Bon I; Grandi N; Miserocchi A; Morini S; Clo A; Furlini G; Gibellini D
    New Microbiol; 2012 Oct; 35(4):407-14. PubMed ID: 23109008
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Chemokine receptor polymorphism and autologous neutralizing antibody response in long-term HIV-1 infection.
    Schønning K; Joost M; Gram GJ; Machuca R; Nielsen C; Nielsen JO; Hansen JE
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jul; 18(3):195-202. PubMed ID: 9665495
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Frequent intratype neutralization by plasma immunoglobulin a identified in HIV type 2 infection.
    Özkaya Şahin G; Månsson F; Palm AA; Vincic E; da Silva Z; Medstrand P; Norrgren H; Fenyö EM; Jansson M
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):470-8. PubMed ID: 23088167
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Minimal incidence of serum antibodies reactive with intact primary isolate virions in human immunodeficiency virus type 1-infected individuals.
    Cavacini LA; Peterson JE; Nappi E; Duval M; Goldstein R; Mayer K; Posner MR
    J Virol; 1999 Nov; 73(11):9638-41. PubMed ID: 10516076
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa.
    Bandawe GP; Moore PL; Werner L; Gray ES; Sheward DJ; Madiga M; Nofemela A; Thebus R; Marais JC; Maboko L; Abdool Karim SS; Hoelscher M; Morris L; Williamson C
    J Infect Dis; 2015 May; 211(9):1461-6. PubMed ID: 25398460
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antiretroviral therapy does not induce HIV type 1-specific neutralizing activity against autologous HIV type 1 isolates.
    Devito C; Hejdeman B; Albert J; Broliden K; Hinkula J
    AIDS Res Hum Retroviruses; 2006 Sep; 22(9):908-11. PubMed ID: 16989617
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Neutralization susceptibility of B subtype variant B" primary HIV-1 isolates. The HEC/FIOCRUZ AIDS Clinical Research Group.
    Bongertz V; Costa CI; Guimarães ML; Grinsztejn B; João Filho EC; Galvão-Castro B; Morgado MG
    Scand J Immunol; 1998 Jun; 47(6):603-8. PubMed ID: 9652830
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Long-term survivors of human immunodeficiency virus type 1 infection.
    Clotet B; Ruiz L; Ibañez A
    N Engl J Med; 1995 Jun; 332(24):1646-7; author reply 1647-8. PubMed ID: 7646661
    [No Abstract]   [Full Text] [Related]  

  • 71. Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus.
    Wrin T; Crawford L; Sawyer L; Weber P; Sheppard HW; Hanson CV
    J Acquir Immune Defic Syndr (1988); 1994 Mar; 7(3):211-9. PubMed ID: 8106963
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals.
    Homsy J; Meyer M; Levy JA
    J Virol; 1990 Apr; 64(4):1437-40. PubMed ID: 2319642
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Complement can neutralize HIV-1 plasma virus by a C5-independent mechanism.
    Sullivan BL; Takefman DM; Spear GT
    Virology; 1998 Sep; 248(2):173-81. PubMed ID: 9721226
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Long-term survivors of human immunodeficiency virus type 1 infection.
    Farid NR
    N Engl J Med; 1995 Jun; 332(24):1647; author reply 1647-8. PubMed ID: 7753148
    [No Abstract]   [Full Text] [Related]  

  • 75. Long-term survivors of human immunodeficiency virus type 1 infection.
    Whyte J
    N Engl J Med; 1995 Jun; 332(24):1647; author reply 1647-8. PubMed ID: 7753149
    [No Abstract]   [Full Text] [Related]  

  • 76. A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy.
    Dinoso JB; Kim SY; Siliciano RF; Blankson JN
    Clin Infect Dis; 2008 Jul; 47(1):102-4. PubMed ID: 18494606
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Neutralization titres and vertical HIV-1 transmission.
    Bongertz V; Costa CI; Veloso VG; Grinsztejn B; Filho EC; Calvet G; Pilotto JH
    Scand J Immunol; 2002 Dec; 56(6):642-4. PubMed ID: 12472677
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization.
    Weber J; Fenyö EM; Beddows S; Kaleebu P; Björndal A
    J Virol; 1996 Nov; 70(11):7827-32. PubMed ID: 8892904
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody.
    McDougal JS; Kennedy MS; Orloff SL; Nicholson JK; Spira TJ
    J Virol; 1996 Aug; 70(8):5236-45. PubMed ID: 8764033
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Comparison of viral burden and phenotype of HIV-1 isolates from lymph nodes and blood.
    Tamalet C; Lafeuillade A; Yahi N; Vignoli C; Tourres C; Pellegrino P; de Micco P
    AIDS; 1994 Aug; 8(8):1083-8. PubMed ID: 7986403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.